Tag Archives: Dr Oystein Fluge
UK rituximab trial fundraising total almost reached
Invest in ME has announced the latest fundraising total for the rituximab/B-cell research, which is a great boost as the research team at UCL are about to visit and discuss the subject with Dr Fluge and Professor Mella in Haukeland University Hospital, … Continue reading
Elevated autoantibodies found in CFS subgroup
Research highlights: β adrenergic and muscarinic acetylcholine receptor autoantibodies are elevated in a subset of patients with Chronic Fatigue Syndrome (CFS). Elevated autoantibodies in CFS correlate with elevated IgG1-3 subclass levels, thyreoperoxidase and ANA antibodies and T cell activation. In … Continue reading
Rituximab leads to B-cell depletion and remission in ME/CFS
Research abstract: Background: Myalgic Encephalopathy/Chronic Fatigue Syndrome (ME/CFS) is a disease of unknown etiology. We previously reported a pilot case series followed by a small, randomized, placebo-controlled phase II study, suggesting that B-cell depletion using the monoclonal anti-CD20 antibody rituximab … Continue reading
Fluge & Mella’s patent application for a CFS treatment
Excerpt from patent application: Inventors: Øystein Fluge & Olav Mella Date of publication 26 11 2014 Nitric oxide donor for the treatment of chronic fatigue syndrome. Description [0001] The present invention relates in a first aspect to a nitric oxide donor for … Continue reading
